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This paper reviews the remarkable impact of H2-receptor antagonists on duodenal ulcer
management. The development and the scientific rationale of these agents are presented, and
efficacy and safety aspects in the short- and long-term treatment of duodenal ulcer disease
discussed. Attention is focused on the possible role of"acid rebound" in ulcer relapse following
the withdrawal of therapy and on the clinical relevance of prolonged suppression of acid
secretion in patients on long-term therapy.
HISTORICAL ASPECTS OF ULCER THERAPY
The medical treatment of peptic ulcer has undergone some interesting changes
since Plinyextolled thevirtues ofthe "milkofan asse orcow" in the firstcenturyA.D.
Frequent milkfeeds, immortalized bythe Sippyregime in the earlytwentieth century
and the Winkelstein milk drip in the mid-1930s, was considered standard ulcer
treatment until as recently as 20 years ago. This therapeutic approach has always
been closely linked with the use of antacids. Celsus used neutralizing earths for
abdominal distress in the first century A.D., Brinton employed bicarbonate prepara-
tions in the mid-1850s, and insoluble, non-absorbable antacids provided the basis of
ulcer therapy from the mid-1920s [1].
The time-honored use of antacid and milk regimens was challenged, over the
years, by anumber ofprovocative approaches based largelyon currentprejudice and,
later, bythe diligent pharmacologicexploration offolklore remedies such ascabbage
juice, potatoes, liquorice, and seaweed. Jean Cruveilhier's case report ofthemanage-
ment ofableeding ulcer in 1830 (Table 1) provides an interesting cameo ofmedicine
in abygone erabut, above all, offers amelancholywarning regarding the limitation of
all forms of medical treatment in the management of bleeding peptic ulcers.
Continental workers, during the post-World War II period, used blood transfusions
alternatingwith subcutaneous novocaine, electro-coagulation ofthepre-frontal lobe,
and other remedies such as ichthyol, and ingenious workers in the West tried
stilbestrol [2], subcutaneous secretin, gastric freezing, and gastric irradiation with
equal enthusiasm. Douthwaite recommended cannabis indica in 1947 for ulcer
patients to "lend enchantment to the dietary" and Gefarnil, a cabbage-juice extract,
enjoyed a short vogue before being superseded by carbenoxolone sodium, a deriva-
tive ofliquorice root. This mucosal strengthening agent, with a seemingly impeccable
scientific rationale, was hailed as a major therapeutic breakthrough in 1968. It was
regarded by some as the "yardstick of a well-proved medical treatment," but was
abandoned shortly after, when it was appreciated that the drug carried with it the
.hazards of hypertension, edema, and potentially lethal hypokalemia [3]. One hesi-
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TABLE 1
Medical Treatment ofBleeding Peptic Ulcer c. 1830
A. Carpenter, aged 29
April 15, 1830 RECURRENCE OF EPIGASTRIC PAIN
April 30 HAEMATEMESIS; carried to Charite
I Bleeding precluded by gross anaemia
Mustard plasters to feet
May 1 SMALLHAEMATEMESIS ONLY
I 20 leeches to epigastrium
Mustard plasters to calves
Rice c eau de Kabel & syrup ofquinces
Diet
May 2 ISQ
l} 20 leeches to anus
Mustard plasters
Same drink
HAEMATEMESIS-DEATH
AUTOPSY: LESSER CURVE GASTRIC ULCER
OPENING OF BRANCH OF CORONARY ARTERY
Jean Cruveilhier (1791-1874)
tates to reflect on the fact that the drug was endorsed by the leading British
gastroenterologists of the day. Xylamide, an alleged mucosal protective agent, was
tried without much success, and amylopectin sulphate, a synthetic polysaccharide
with an antipeptic effect, suffered the same fate [4].
The therapeutic turmoil of the late 1960s reflected the profound lack of any
meaningful advance in the understanding of the duodenal ulcer diathesis and, in
general, treatment continued to be governed by the well-worn equation of ulcer
etiology-acid pepsin aggression versus impaired mucosal resistance. This approach
provided the rationale forthe development ofpotent acid inhibitors on the one hand
and effective mucosal protective ulcer-healing agents on the other. Recent apprecia-
tion of the importance ofH. pylon in the etiology of duodenal ulcer disease and, in
particular, its role in duodenal relapse, has resulted in a shift in emphasis from the
healing of the ulcer to the possible cure of the disease. The therapeutic pendulum
continues to swing.
DEVELOPMENT OF H2-RECEPTOR BLOCKERS
The fundamental discovery by Black and co-workers [5] of the so-called H2-
receptors, identified by the selective antagonist burinamide, was ofprofound impor-
tance in unraveling the physiology ofhistamine and gastrin. It also ushered in a new
eraofulcertherapeutics. Burinamidewas neithersufficientlypotent norwell enough
absorbed after oral administration to warrant further clinical study. Modification of
burinamide to yield less polar, more active H2-receptor antagonists, however, led in
turn to metiamide [6] and cimetidine [7]. The former, while active by mouth and
640ACID INHIBITION, ULCER RELAPSE, AND ACID REBOUND
CH2-S-CH2-CH2-NH-C-NHCH3
tNtCH3 N-CN N 2JCH3 I
H
Cimetidine
H3C 4
,N-CH2 0 CH2-S-CH2-CH2-NH-C-NHCH3
H3C
2 CItO3
Ranitidine
CH2-S-CH2-CH2-C-NH2
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CN-CH2-0-CH2-CH2-CH2-NH-C-CH2---CH3 FIG. 1. Chemical structures of cur-
Roxatidine acetate rently available H2-receptor antagonists.
clinically effective, showed evidence of bone-marrow toxicity and immunological
changes [8] and waswithdrawn from further clinical study.
By a happy accident of timing, cimetidine, the potent H2-receptor blocker, was
developed at about the same time as the fiber-duodenoscope became generally
available, and the concept of controlled clinical trials firmly established. The
unequivocal superiority of cimetidine over placebo in short-term duodenal ulcer
healingwassoonconfirmedbyaseriesofsuperblyorchestrated,worldwide, endoscop-
ically controlled studies. The scientific appeal and convincing short-term effect of
cimetidine prompted Wormsley to state, in 1977, that "it is already possible to
conclude that the H2-receptor blockers make all other medical treatment of duode-
nal ulcer obsolete." The effect ofcimetidine and, with it, realization ofthe financial
potential of the ulcer market, set the scene for an ongoing race for the newer
competitive H2-receptor blockers and, indeed, the pharmaceutical breeching ofboth
the outer and innerbastions ofthe parietal cell. Ranitidine became available in 1980,
and famotidine, nizatidine, and roxatidine were introduced in many countries over
the next few years. There can be no class of drug that has been researched so
thoroughly.
CHEMISTRY
The H2-receptor antagonists are characterized by two functional groups-an
aromatic ring system and a polar (unchanged at physiological pH) planar group-
which are connected by a flexible chain. The chemical structures of the currently
available H2-receptor antagonists are shown in Fig. 1. Cimetidine is an imidazole
derivative, ranitidine and nizatidine belong to the basically substituted furans and
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TABLE 2
Dosages for Ulcer Therapy ofCurrently Available
H2-Receptor Antagonists
H2-Receptor Ulcer Therapy
Antagonist Dose (mg/day)
Cimetidine 800
Ranitidine 300
Famotidine 40
Roxatidine 150
Nizatidine 300
thiazoles, respectively, famotidine is a member ofthe guanidino-thiazole group, and
roxatidine belongs to the aminoalkylphenoxy series. The approximately equipotent
daily dose ofthese agents, shown inTable 2, ranges from 40 mgforfamotidine to 800
mg for cimetidine. Molecular modeling studies suggest that the increased potencyof
famotidine, on aweightbasis, is due to its greater H2-receptor affinity [9].
EFFICACY AND DURATION OF SHORT-TERM THERAPY
Duodenal ulcer healing studies show that approximately 70 to 80 percent ofulcers
willbe healed afterfourweeks' treatmentwith an H2-receptor antagonist andthat 90
to 95 percent will be healed after eight weeks. The McMaster group defined three
primary determinants of healing derived from antisecretory data: the degree and
duration ofsuppression of24-hour intragastric acidity, and the length of treatment.
They noted that a longer duration ofantisecretory effect and/or a longer duration of
treatment are ofgreater importance than potency of acid suppression for duodenal
ulcer healing [10,11].
Earlier reports had suggested that ulcer healing, once initiated, may continue
despite withdrawal of the H2-receptor antagonist. Johannessen et al. [12] treated
duodenal ulcer patients with cimetidine for four weeks or cimetidine for one week
followed by placebo for three weeks. The four-week healing rate in both groups was
68 percent. Lance and Gazzard [13] had previously studied two groups of patients
with duodenal ulcer treated with cimetidine for six weeks or cimetidine given until
they became asymptomatic (about two weeks). The relapse rates after three months
were similar in both groups. It is difficult to reconcile the findings in these two
relatively small studieswith those ofthe more substantial McMaster analyses.
DOSAGE REGIMENS
The recommended dosage regimen ofcimetidine has evolved from the four times
daily (qds) to the twice daily (bd) and eventually a single daily dose, whereas the
dosage regime of ranitidine has evolved from the bd to a single nocturnal dose. The
switch to once-a-day dosing, prompted by the potential threat of once-a-day dosing
with the newerH2-receptor antagonists andomeprazole, wasjustified on the grounds
of better compliance and the need to achieve better control of nocturnal acid
secretion.
The concept of selective suppression ofnocturnal acid secretion is applied widely
in the marketing of H2-receptor antagonists [14]. Clinical studies, however, suggest
that morning or evening dosing with full doses of these drugs achieves comparable
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duodenal ulcer healing rates [15-19]. The data thus suggest that selective suppres-
sion ofnocturnal acid secretion is not essential for duodenal ulcer healing, and that a
prolonged period ofacid inhibition during the day may suffice.
By the same token, Merki et al. [20] showed that early evening dosing with a full
dose of an H2-receptor antagonist produces a more profound decrease of 24-hour
intragastric acidity than a similar dose taken at bedtime, but studies confirming the
advantage ofthis early evening regimen in terms ofulcer healing are still awaited.
RELAPSE RATES
Recurrent rates following initial duodenal ulcer healing with an H2-receptor
antagonist-ofthe orderof70-90 percent in oneyear-were appreciablyhigherthan
those reported in the pre-cimetidine era. Langman [21], in his review on the
long-term course of duodenal ulcer, reported relapse rates of 20-45 percent after
about five years, and Spiro [22] regarded duodenal ulcer as a tame disorder which
"did not seem to require perpetual therapy from the physician or eternal vigilance
from its owner." These differences could perhaps be reconciled with the fact that
approximately 25 percent of endoscopic recurrences are unassociated with symp-
toms, and that clinicallymild relapses account for a proportion ofthe remainder.
The reported increase also raised the question as to whether the H2-receptor
antagonists do not, in themselves, invite a higher relapse rate [3]. Relapse rates after
initial treatment with colloidal bismuth agents are appreciably, and often signifi-
cantly, lower than those following initial treatment with an H2-receptor antagonist,
and a similar advantage has been reported in most studies in patients healed initially
with sucralfate [23]. The reason for the trend toward lower relapse rates following
ulcer healingwith mucosal protective agents is not clear. The antimicrobial action of
the colloidal bismuth agents againstH.pyloni, discussed elsewhere in thissymposium,
is clearly a factor, and differences in the quality ofulcer healing following treatment
with an H2-receptor antagonist and the mucosal protective agents may have some
relevance. A third possibility relates to the concept of "acid rebound" following
treatment with an H2-receptor antagonist [24].
REBOUND ACID HYPERSECRETION
The evidence for a rebound increase in gastric acid secretion after withdrawal of
H2-receptorantagonistsis strongin controlsubjects and in duodenalulcerpatients in
remission [25-31]. The data in all but one [32] of the studies in patients following
successful treatment of an active duodenal ulcer is less convincing [33-37], but this
findingmaybe linkedwith the tendencyfor acid secretory responses to fallwithulcer
healing. Sucralfate healing is consistently associated with a significant decrease in all
acid secretory parameters, whereas responses after healing with an H2-receptor
antagonist show little change over pre-treatment levels. The failure of the acid
secretory responses to fall, despite ulcer healing, has been construed as evidence of
H2-receptor antagonist-related "acid rebound" [34].
Several views have been advanced to identify the cause of "acid rebound"
following treatment with an H2-antagonist. "Upregulation" of the H2-receptors has
been suggested [27], but appropriate H2-receptor counts have not been performed.
Hypergastrinemia induced by prolonged acid inhibition has also been suggested as a
possible mechanism for acid hypersecretion after withdrawal oftherapy, but studies
withvarious H2-receptor antagonists have shown that the raisedgastrin levels during
643I.N. MARKS
therapy revert to normal before rebound acid hypersecretionbecomes apparent [28].
It is not known whether the development of "tolerance" during treatment [38,39],
defined as the decreased effectiveness of H2-receptor blockade with time, translates
into "acid rebound" once treatment iswithdrawn.
The clinical relevance of "acid rebound" after treatment with an H2-receptor
antagonist cannot be excluded, despite the transient nature of this phenomenon.
Available data suggest that the majority ofrelapses occurwithin the first few months
following documented ulcer healing and withdrawal of treatment [40], and a close
correlation between acid secretory status after duodenal ulcer healing and early
relapse has been reported [41,42]. The tantalizing possibility that H. pylori and
various mediators associated with inflammation and duodenitis may play a role in
this phenomenon is yet to be investigated.
LONG-TERM STRATEGY
Chronic duodenal ulcer is a relapsing disease, and it is generally accepted that a
long-term treatment strategy is required for the majorityofpatients. Appreciationof
the value of continuous low-dose treatment with an H2-receptor antagonist in
reducing the liability to relapse established the concept of maintenance therapy-
and added a new dimension to the management ofduodenal ulcer. The dilemmawas
aptly expressed in the title of an editorial in The British MedicalJoumal in 1978 [43]:
"Cimetidine for ever (and ever and ever....)?" Some sceptics [3] likened cimetidine
to an unsuccessful marriage-"a moment of bliss and a life-time of maintenance."
They went further. The rationale of treating all ulcer patients with maintenance
therapy after initial ulcer healing was questioned on the grounds of cost, possible
long-term side effects, and, indeed, efficacy. Although maintenance treatment with
ranitidine is marginally superior to that with cimetidine [44], one-year relapse rates
with H2-receptor antagonists are usually of the order of 30 percent. Furthermore,
relapse rates on stopping maintenance therapy are similar to those found in patients
after short-term healing [45].
There are other therapeutic options. Some patients with less aggressive disease
are treatedwith recurrent full-dose courses foreach relapse (intermittent treatment)
[46], while others take the drug for a few days on an ad hoc basis for symptomatic
relief (on-demand treatment) and report to their doctors only in the event of
persistent or severe symptoms. The hazard of an increased incidence of complica-
tionswith the latter twooptions has notbeen fullyevaluated. Maintenance treatment
with cimetidine may be cost-effective in the first two years after duodenal ulcer
healing [47], but there is no consensus on this regimen [48].
The place of maintenance treatment with an H2-receptor antagonist in patients
with a history of frequent and severe relapses and in the elderly with a history of
complications appeared, until recently, tobe unassailable. This orthodoxapproach is
now being challenged by an increasing appreciation of the role of H. pylon in
duodenal ulcer relapse, and by remarkable developments in mini-access surgery.
There is strong evidence that eradication ofH. pylon is associated with a dramatic
reduction, andvirtual elimination, ofulcer relapse [49], and manyworkers are ofthe
opinion that H. pylon eradication is the preferred option in all patients being
considered for maintenance therapy-or elective duodenal ulcer surgery. Laparo-
scopic vagotomy may yet prove a significant and cost-effective alternative to mainte-
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nance therapy in patients with aggressive duodenal ulcer disease in whom H.pyloni
eradication cannot be achieved.
SAFETY ASPECTS
The H2-receptor antagonists have a remarkable safety record, surprising inview of
thestrategic location oftheH2-receptors in other organs [50].
SideEffects
Headache, nausea, dizziness, constipation, vomiting, and abdominal pain are
rarely encountered; anti-androgenic side effects such as gynecomastia and impo-
tence have been recorded in patients receiving large doses ofcimetidine or, even less
commonly, ranitidine. Central nervous system side effects in the elderly, such as
mental confusion, restlessness, agitation, and depression, have also been reported in
patients treatedwith cimetidine or ranitidine [9].
DrugInteractions
Several drug interactions have been recorded in patients receiving cimetidine.
These include interactionswith theophylline, warfarin, phenytoin, propanolol, meto-
propol, diazepam, and lidocain. It is suggested that cimetidine inhibits the hepatic
metabolism ofthese and other drugsbybinding directly tocytochrome p-450, amajor
component of the mono-oxygenase system, thus reducing the substrate interactions
with other drugs. Caution should therefore be exercised in prescribing cimetidine to
patients on these drugs. The interaction between ranitidine and cytochrome p-450 is
much lower than that between cimetidine and cytochrome p-450, and it does not
appear to occur with famotidine [9].
Interference with the gastric alcohol dehydrogenase (ADH) system by certain
H2-receptor antagonists during acute alcohol intake may increase the systemic
bioavailability of alcohol and raise peak blood alcohol levels by as much as 20
percent. This reaction applies particularly to cimetidine and, to a lesser extent,
nizatidine [51,52].
Suppression ofAcid Secretion
The ongoing debate regarding the effect of sustained pharmacologic suppression
of acid secretion has focused largely on the relevance of acid secretion in health and
disease and, in particular, the possible risk ofgastric cancer. These concerns put the
brake on the development of the unsurmountable or irreversible H2-antagonist and
stalled, for a while, the clinical trials with omeprazole. They have also prompted an
enquiry as to the feasibility of somewhat less potent, reversible proton pump
inhibitors.
Acid is required to facilitate peptic digestion of food and foreign antigens, favors
the release ofvitamin B12 from food, increases Fe++, Ca++, and trace metal solubility
and absorption and, as important, provides a barrier against infectious agents. It is
well established that a decrease of intragastric acidity leads to intragastric bacterial
colonization [53,54], and this condition, in turn, may expose the patient to the risk of
enteric infections. This problem is minimal with present dose regimens of H2-
receptor antagonists, but drug regimens which inhibit acid secretion over the full
24-hour period may be another matter. Patients in the post-operative or intensive-
care setting represent an important riskgroup. Such patients may suffer an increased
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incidence of nosocomial pneumonia and sepsis as a result of gastric bacterial
colonization due to pharmacologic suppression of gastric acidity in stress ulcer
prophylaxis [55].
Putative mechanisms linking prolonged acid suppression with gastric cancer have
been comprehensively reviewed by Soybel and Modlin [56]. The lingering hypothesis
that intragastric bacterial overgrowth maylead to raised gastric nitrite and N-nitroso
levels does not appear to have any clinical relevance in patients on current H2-
receptor antagonist dosage regimens, and the relatively modest rise in serum gastrin
levels consequent upon acid suppression in this setting is hardly a matter ofconcern.
A third mechanism relates to the finding of epithelial proliferation and neoplastic
transformation in rats treated with a variety of potent candidate H2-receptor
antagonists. Tiotidine caused dysplasia orneoplasia in the distal stomach, SKF93479
elicited focal hyperplasia and hyperkeratosis of the forestomach, and lupitidine
produced squamous carcinomas of the stomach. The absence of such changes in
experimental animals treated with the currently used H2-receptor antagonists sug-
gests that carcinogenic potential is linked to the structural properties of individual
agents rather than to their efficacy in inhibiting acid secretion [56].
QUO VADIS
The hitherto dominant position ofH2-receptor antagonists in ulcer therapy-they
accounted for no less than 85 percent of all ulcer tablets used in the U.S.A. in
1989-is currently being challenged by the irreversible proton pump inhibitors, on
the one hand, and by evolving concepts on the role of H. pylon in duodenal ulcer
disease on the other [57]. These andotherfactors such asmucosal protection, growth
factors, and the possible development of less potent, reversible proton pump
inhibitors promise to keep the ulcer debate active, but the efficacy, safety, and long
track record ofthe H2-receptor blockers should ensure their place in duodenal ulcer
therapy for many years to come. History has taught us, however, that nothing is
sacrosanct in ulcer therapeutics.
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